{"id":"NCT00829166","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","officialTitle":"A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2012-07","completion":"2015-09","firstPosted":"2009-01-26","resultsPosted":"2013-04-23","lastUpdate":"2016-10-31"},"enrollment":991,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Trastuzumab emtansine","otherNames":["T-DM1","Trastuzumab-MCC-DM1","RO5304020"]},{"type":"DRUG","name":"Lapatinib","otherNames":["Tykerb","Tyverb"]},{"type":"DRUG","name":"Capecitabine","otherNames":["Xeloda"]}],"arms":[{"label":"Trastuzumab emtansine","type":"EXPERIMENTAL"},{"label":"Lapatinib + Capecitabine","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.","primaryOutcome":{"measure":"Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)","timeFrame":"From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)","effectByArm":[{"arm":"Trastuzumab Emtansine","deltaMin":53.5,"sd":null},{"arm":"Lapatinib + Capecitabine","deltaMin":61.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":17},"locations":{"siteCount":323,"countries":["United States","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Colombia","Denmark","Finland","France","Germany","Hong Kong","India","Italy","Mexico","New Zealand","Philippines","Poland","Portugal","Russia","Singapore","Slovenia","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["28526536","23020162","22437872"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":92,"n":490},"commonTop":["Diarrhoea","Nausea","Fatigue","Palmar-Plantar erythrodysaesthesia syndrome","Vomiting"]}}